Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.

BMC Cancer · 2011 · PMC3052196 · PMID 21324142

Europe PMC DOI

hedged sentence

0.0998

closest p · 2.0× alpha

0.0998

boldest claim

The sentences

did not reach statistical significancep = 0.0998so close (0.05 < p ≤ 0.1)

This difference in PFS and OS persisted when analysis was limited to patients with PR or SD on IM, after exclusion of progressive patients, although the difference in PFS did not reach statistical significance in this analysis (median 29.7 vs not reached, p = 0.0998 and 42.2 vs not reached, p = 0.0333 for PFS and OS respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.